Narayana Narasimhan

Narayana Narasimhan, Ph.D. joined Kojin as Senior Vice President, Preclinical Safety and DMPK in April 2024.

Dr. Narasimhan brings over 35 years of drug discovery and development and regulatory experience to Kojin. Dr. Narasimhan is a subject-matter expert in drug metabolism, bioanalysis, and clinical pharmacology. Most recently, he was Senior Vice President of DMPK & Preclinical Safety at Theseus Pharmaceuticals, where he played key leadership roles in the IND application and clinical development of THE-630 and the discovery of THE-349. Prior to Theseus, Dr. Narasimhan worked at Verastem Oncology and played a key role in the successful EU approval of Copiktra®.

Prior to this, Dr. Narasimhan worked for 13 years at ARIAD Pharmaceuticals, where he successfully built a DMPK and preclinical safety department and contributed to the successful registration of Iclusig® (worldwide) and Alunbrig® (U.S. and EU), as well as the IND and Phase 1 clinical trial of mobocertinib. Earlier in his career, Dr. Narasimhan worked at Merck & Co., Inc. and Bristol-Myers Squibb in various scientific positions.

Dr. Narasimhan earned his Ph.D. in chemistry from Vanderbilt University and received postdoctoral training in drug metabolism at the University of Kansas.

Dr. Narasimhan is a co-author of more than 50 publications and has authored over 200 technical reports for regulatory submissions.